Biomarkers for drug-induced liver injury
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Of the estimated 10,000 documented human drugs, more than 1000 have been associated with drug-induced liver injury (DILI), although causality has not always been established clearly. Numerous biomarkers for DILI have been explored, but less than ten are adopted or qualified as valid by the US FDA. The biomarkers for DILI are individual or a panel of proteins, nucleic acids or metabolites from various sources, such as the liver, blood and urine. While most DILI biomarkers are drug independent, some possibly 'drug-specific' DILIs have been explored, but specificity and sensitivity of both types need to be improved for the diagnosis of DILI during drug development and in clinical practice. Novel approaches for DILI biomarkers have been actively investigated recently, but produced mainly animal-based biomarkers, which are possibly useful for drug development, but are not suitable or have not been validated for clinical applications. This review summarizes the current practice and future perspectives for DILI biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Idiosyncratic drug-induced liver injury: an overview
Hussaini, S. H., & Farrington, E. A. (2007) · Expert Opinion on Drug Safety · doi:10.1517/14740338.6.6.673 · Cited by 183
James, L. P., Letzig, L., Simpson, P. M., Capparelli, E., Roberts, D. W., Hinson, J. A., Davern, T. J., & Lee, W. M. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.026195 · Cited by 175
Drug-induced liver injury: Is it somehow foreseeable?
Tarantino, G., Minno, M. N. D. D., & Capone, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2817 · Cited by 137
Edgar, A. D., Tomkiewicz, C., Costet, P., Legendre, C., Aggerbeck, M., Bouguet, J., Staels, B., Guyomard, C., Pineau, T., & Barouki, R. (1998) · Toxicology Letters · doi:10.1016/s0378-4274(98)00042-3 · Cited by 71
Cited by
Pathogenesis of Idiosyncratic Drug-Induced Liver Injury and Clinical Perspectives
Fontana, R. J. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.032 · Cited by 313
Cheng, D., Peng, J., Lv, Y., Su, D., Liu, D., Chen, M., Yuan, L., & Zhang, X. (2019) · Journal of the American Chemical Society · doi:10.1021/jacs.9b01374 · Cited by 308
Lu, X., Hu, B., Shao, L., Tian, Y., Jin, T., Jin, Y., Ji, S., & Fan, X. (2013) · Food and Chemical Toxicology · doi:10.1016/j.fct.2013.01.020 · Cited by 70
Mechanism of Idiosyncratic Drug Induced Liver Injury (DILI): Unresolved Basic Issues
Teschke, R., & Uetrecht, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-ubih-05 · Cited by 58
Drug-Induced Liver Injury in Children: Clinical Observations, Animal Models, and Regulatory Status
Shi, Q., Yang, X., Greenhaw, J. J., Salminen, A. T., Russotti, G. M., & Salminen, W. F. (2017) · International Journal of Toxicology · doi:10.1177/1091581817721675 · Cited by 37
Self-citationTeschke, R., Eickhoff, A., Brown, A. C., Neuman, M. G., & Schulze, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms21010212 · Cited by 30
Teschke, R. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1539077 · Cited by 24
Osaki, M., Kosaka, N., Okada, F., & Ochiya, T. (2014) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0065-0 · Cited by 13
Metadata
- Authors
- Shi, Q., Hong, H., Senior, J., & Tong, W.
- Venue
- Expert Review of Gastroenterology & Hepatology
- Publisher
- Informa UK Limited
- Published
- 2010-04
- Volume
- 4
- Issue
- 2
- Pages
- 225-234
- ISSN
- 1747-4124 (ISSN-L)
- 1747-4132
- OpenAlex
- W1988680583
- Cited by
- 89
- References
- 6
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.